A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Trial Profile

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms EMERGE
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 27 Sep 2015 Results of post-hoc analysis (n=328) presented at the ASCO - Breast Cancer Symposium 2015
    • 06 Apr 2015 According to a Celldex Therapeutics media release, the data from this study supported the initiation of the phase 2 METRIC study. (See CT profile 700239414)
    • 06 Apr 2015 Results published in a Celldex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top